Prevalence, pathophysiology, predictive factors, and prognostic significance of anemia in cancer chemotherapy

  • M. R. Nowrousian


As a common symptom in cancer, anemia is often induced either directly or indirectly by the malignant disease itself or its treatment. The prevalence of anemia depends on one side on the type and stage of malignancy and on the other side on the type, schedule and intensity of treatment. Hematological malignancies, particularly myeloid disorders, are generally more often associated with anemia than solid tumors but, depending on the type of treatment, the latter may be associated with anemia and require red blood cell (RBC) transfusions in a similarly high proportion of patients (Skillings et al. 1993; Coiffier et al. 2001). Anemia and the need for transfusions are also more frequently associated with advanced stage of diseases than early stage (Durie and Salmon 1975; Binet et al. 1977; Moullet et al. 1998; Barrett-Lee et al. 2000). Preexisting anemia related to cancer or prior treatment usually worsens during radiotherapy and chemotherapy, and in a considerable number of patients, radiotherapy and chemotherapy as such produce anemia, primarily due to their myelosuppressive effect (Tables 1–3) (Skillings et al. 1993; Estrin et al. 1999; Groopman and Itri 1999; Lammering et al. 1999; Barrett-Lee et al. 2000; Harrison et al. 2000; Coiffier et al. 2001).


Ovarian Cancer Multiple Myeloma Clin Oncol Chronic Lymphocytic Leukemia Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Corfu-A Study Group (1995) Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13: 921–928Google Scholar
  2. 2.
    Abels R, Gordon D, Nelson R, Krantz K, Ageeb M, Goon B, Liebow B (1991) Transfusion practice in advanced cancer patients. Blood 78 (Suppl 1): 474a (Abstract)Google Scholar
  3. 3.
    Abels RI (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19 (Suppl 8): 29–35PubMedGoogle Scholar
  4. 4.
    Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A (Suppl 2): S2–58CrossRefGoogle Scholar
  5. 5.
    Abels R, Larholt K, Nelson R, Young D (1994) Risk of transfusion in small cell lung cancer patients receiving chemotherapy. Blood 84 (Suppl 1): 664a (Abstract)Google Scholar
  6. 6.
    Abratt RP, Hacking DJ, Goedhals L, Bezwoda WR (1997) Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Semin Oncol 24 (Suppl 8): S18 - S23Google Scholar
  7. 7.
    Alberts DS, Green S, Hannigan EV, O’Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolies CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706–717PubMedGoogle Scholar
  8. 8.
    Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821–1826PubMedGoogle Scholar
  10. 10.
    Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15: 2090–2096Google Scholar
  11. 11.
    Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18: 4–11PubMedGoogle Scholar
  12. 12.
    Bajorin DF, McCaffrey JA, Hilton S, Mazumdar M, Kelly WK, Scher HI, Spicer J, Herr H, Higgins G (1998) Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol 16: 2722–2727PubMedGoogle Scholar
  13. 13.
    Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93–97PubMedCrossRefGoogle Scholar
  14. 14.
    Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46: 459–466PubMedCrossRefGoogle Scholar
  15. 15.
    Berry WR, Laszlo J, Cox E, Walker A, Paulson D (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763–775PubMedCrossRefGoogle Scholar
  16. 16.
    Binet JL, Lepoprier M, Dighiero G, Charron D, D’Athis P, Vaugier G, Beral HM, Natali JC, Raphael M, Nizet B, Follezou JY (1977) A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 40: 855–864PubMedCrossRefGoogle Scholar
  17. 17.
    Blohmer JU, Paepke S, Böhmer D, Ernhardt B, Sehouli J, Elling D, Lichtenegger W (2001) [Adjuvant chemotherapy of cervix carcinoma–results of a phase II study]. Zentralbl Gynäkol 123: 286–291Google Scholar
  18. 18.
    Budd GT, Green S, O’Brayan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O’Sullivan J, Osborne CK (1995) Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an Intergroup study. J Clin Oncol 13: 831–839PubMedGoogle Scholar
  19. 19.
    Bush RS (1986) The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12: 2047–2050PubMedCrossRefGoogle Scholar
  20. 20.
    Cabanillas F, Burke JS, Smith TL, Moon TE, Butler JJ, Rodriguez V (1978) Factors predicting for response and survival in adults with advanced non-Hodgkin’s lymphoma. Arch Intern Med 138: 413–418PubMedCrossRefGoogle Scholar
  21. 21.
    Canaparo R, Casale F, Muntoni E, Zara GP, Della Pepa C, Berno E, Pons N, Fornari G, Eandi M (2000) Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 50: 146–153PubMedCrossRefGoogle Scholar
  22. 22.
    Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478–1484Google Scholar
  23. 23.
    Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA (1995) Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin’s disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol 13: 2005–2011Google Scholar
  24. 24.
    Canetta R, Rozencweig M, Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 (Suppl A): 125–136PubMedCrossRefGoogle Scholar
  25. 25.
    Carabantes FJ, Benavides M, Trujillo R, Cobo M, Hebrero ML, Garcia S, Gomez D, Reche P, Breton JJ, Marquez A, Paredes G, Juarez C (1999) Epoetin alpha in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy. A prospective randomized study. Proc Am Soc Clin Oncol 18: 596a (Abstr 2303)Google Scholar
  26. 26.
    Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214–2221PubMedCrossRefGoogle Scholar
  27. 27.
    Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 533–537Google Scholar
  28. 28.
    Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314–322PubMedGoogle Scholar
  29. 29.
    Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, Rugarli C (1997) Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 31: 286–291PubMedGoogle Scholar
  30. 30.
    Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7: 1018–1026PubMedGoogle Scholar
  31. 31.
    Coiffier B (2000) The impact and management of anaemia in haematological malignancies. Med Oncol 17 (Suppl 1): S2 - S10PubMedCrossRefGoogle Scholar
  32. 32.
    Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37: 1617–1623PubMedCrossRefGoogle Scholar
  33. 33.
    Conlan MG, Armitage JO, Bast M, Weisenburger DD (1991) Clinical significance of hematologic parameters in non-Hodgkin’s lymphoma at diagnosis. Cancer 67: 1389–1395PubMedCrossRefGoogle Scholar
  34. 34.
    Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L, Camino F, Dottini M, Mossetti C, Gercio E, Gatti M, Niliquini PN, Prelato ML, Durando C, Giaccone G, Calciati A, Farinini D, Centonze M, Rugiati S, Parodi G, Messineo M, Strace A, Bernardini G, Misurale F, Alessandri S, Casini M, Ragni N, Foglia G, Bentivoglio G, Pescetto G (1986) A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 4: 965–971PubMedGoogle Scholar
  35. 35.
    Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18: 3108–3114PubMedGoogle Scholar
  36. 36.
    Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, Deakin DP, Crowther D (1989) Prognostic factors in high and intermediate grade non-Hodgkin’s lymphoma. Br J Cancer 59: 276–282PubMedCrossRefGoogle Scholar
  37. 37.
    Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW (1996a) Topotecan, an active drug in the second-line treatment of epitheliai ovarian cancer: results of a large European phase II study. J Clin Oncol 14: 3056–3061PubMedGoogle Scholar
  38. 38.
    Creemers GJ, Gerrits CJ, Schellens JH, Planting AS, van der Burg ME, van Beurden VM, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J (1996b) Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14: 2540–2545Google Scholar
  39. 39.
    Daneryd P, Svanberg E, Körner U, Lindholm E, Sandström R, Brevinge H, Pettersson C, Bosaeus I, Lundholm K (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58: 5374–5379PubMedGoogle Scholar
  40. 40.
    Davidson NG (1996) Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 23 (Suppl 11): 6–10PubMedGoogle Scholar
  41. 41.
    de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N (1995) Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 13: 1623–1631PubMedGoogle Scholar
  42. 42.
    Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Homer D, Demaille A (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423–426PubMedGoogle Scholar
  43. 43.
    Del Mastro L, Venturini M, Lionetto R et al (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721PubMedGoogle Scholar
  44. 44.
    Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412–3425Google Scholar
  45. 45.
    Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, Mignot L, Chazard M, Garet F, Onetto N et al (1995) Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22 (Suppl 8): 33–39PubMedGoogle Scholar
  46. 46.
    Dietz A, Rudat V, Conradt C, Vanselow B, Wollensack P, Staar S, Eckel H, Völling P, Schröder M, Wannenmacher M, Müller RP, Weidauer H (2000) [Prognostic value of hemoglobin level for primary radiochemotherapy of head-neck carcinomas]. HNO 48: 655–664Google Scholar
  47. 47.
    Dische S (1991) Radiotherapy and anaemia–the clinical experience. Radiother Oncol 20 (Suppl 1) 35–40PubMedCrossRefGoogle Scholar
  48. 48.
    Doll DC, Weiss RB (1985) Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 69: 777–782PubMedGoogle Scholar
  49. 49.
    Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangie T, Scholl S, Sastre X, Pouillart P (1996) Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 6: 47–49PubMedGoogle Scholar
  50. 50.
    Dunst J (2000) Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27 (Suppl 4): 4–8; discussion 16–17Google Scholar
  51. 51.
    Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842–854Google Scholar
  52. 52.
    Dwilewicz-Trojaczek J, Sek S (1996) Prognostic factors in patients with lymphoplasmacytic lymphoplasmacytoid lymphoma in stage IV of clinical progression. Pol Tyg Lek 51: 266–268PubMedGoogle Scholar
  53. 53.
    Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748–1753PubMedGoogle Scholar
  54. 54.
    Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetto R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654–2666PubMedGoogle Scholar
  55. 55.
    Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, Priest K (1995) Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71: 366–370PubMedCrossRefGoogle Scholar
  56. 56.
    Emrich LJ, Priore RL, Murphy GP, Brady MF (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45: 5173–5179PubMedGoogle Scholar
  57. 57.
    Estrin JT, Schocket L, Kregenow R, Henry DH (1999) A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 4: 318–324PubMedGoogle Scholar
  58. 58.
    Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13: 1430–1435PubMedGoogle Scholar
  59. 59.
    Faylona EA, Loehrer PJ, Ansari R, Sandler AB, Gonin R, Einhorn LH (1995) Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol 13: 1209–1214PubMedGoogle Scholar
  60. 60.
    Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E (1997) Prognosis of patients with advanced Hodgkin’s disease: evaluation of four prognostic models using 344 patients included in the Groupe d’Etudes des Lymphomes de l’Adulte Study. Cancer 80: 1124–1233 •Google Scholar
  61. 61.
    Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S (1985) Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3: 54–64PubMedGoogle Scholar
  62. 62.
    Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, von Hoff DD (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245–1251PubMedGoogle Scholar
  63. 63.
    Forastiere AA, Neuberg D, Taylor SGt, DeConti R, Adams G (1993) Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. J Natl Cancer Inst Monogr 15: 181–184PubMedGoogle Scholar
  64. 64.
    Fossa A, Brandhorst D, Myklebust JH, Seeber S, Nowrousian MR (1999) Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma. Exp Hematol 27: 1621–1626PubMedCrossRefGoogle Scholar
  65. 65.
    Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Ki Hong W, Raber M (1994) Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12: 1238–1244PubMedGoogle Scholar
  66. 66.
    Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, Hakes T (1994a) Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12: 2301–2308PubMedGoogle Scholar
  67. 67.
    Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT (1994b) Phase II trial of docetaxel in patients with stage III and IV nonsmall-cell lung cancer. J Clin Oncol 12: 1232–1237PubMedGoogle Scholar
  68. 68.
    Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, Dini E, Resegotti L, Damasio EE, Silingardi V (1994) Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 13: 307–316Google Scholar
  69. 69.
    Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245–1252PubMedGoogle Scholar
  70. 70.
    Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, Nishiwaki Y, Niitani H, Sakuma A (1994) A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 11: 385–391Google Scholar
  71. 71.
    Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N (1994) [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho 21: 1033–1038Google Scholar
  72. 72.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882Google Scholar
  73. 73.
    Gallagher GJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA (1986) Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4: 1470–1480Google Scholar
  74. 74.
    Gamucci T, Thorel MF, Frasca AM, Giannarell D, Clabresi F (1993) Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 29A (Suppl 2): 13–14CrossRefGoogle Scholar
  75. 75.
    Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G (1994) Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12: 2094–2101PubMedGoogle Scholar
  76. 76.
    Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A: 243248Google Scholar
  77. 77.
    Gelb AB (1997) Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 981–986PubMedCrossRefGoogle Scholar
  78. 78.
    Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699PubMedGoogle Scholar
  79. 79.
    Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715PubMedCrossRefGoogle Scholar
  80. 80.
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  81. 81.
    Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, Merli F, lannitto E, Tura S, Ascari E (2001) Comparison of prognostic models in patients with advanced Hodgkin disease. Cancer 91: 1467–1478PubMedCrossRefGoogle Scholar
  82. 82.
    Gonzalez Baron M, Feliu J, Garcia Giron C, Espinosa J, Martinez B, Blanco E, Crespo MC, Ordonez A, Espinosa E, de Castro J, Juarez F, Colmenarejo A (1997) UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 54: 24–29Google Scholar
  83. 83.
    Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, et al (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen ( CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327: 1342–1349Google Scholar
  84. 84.
    Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, Herman JG, Garrett PG, Chua T, Duncan W et al (1989) Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 142: 1448–1453PubMedGoogle Scholar
  85. 85.
    Grau C, Overgaard J (1998) Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P (eds) Blood perfusion and microenviroment of human tumors. Springer, Berlin Heidelberg New York, pp 101–102CrossRefGoogle Scholar
  86. 86.
    Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AK (1996) Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14: 2674–2681PubMedGoogle Scholar
  87. 87.
    Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528–1536PubMedCrossRefGoogle Scholar
  88. 88.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634PubMedCrossRefGoogle Scholar
  89. 89.
    Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA (1997) Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 15: 3464–3470PubMedGoogle Scholar
  90. 90.
    Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr MS, Randolph J, Schacter LP, Greco FA (1995) Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol 13: 1436–1442PubMedGoogle Scholar
  91. 91.
    Hamblin TJ, Orchard JA, Myint H, Oscier DG (1998) Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol 16: 3209–3210PubMedGoogle Scholar
  92. 92.
    Harrison LB, Shasha D, White C, Ramdeen B (2000) Radiotherapy-associated anemia: the scope of the problem. Oncologist 5: 1–7CrossRefGoogle Scholar
  93. 93.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339: 1506–1514Google Scholar
  94. 94.
    Heddens DK, Alberts DS, Garcia DJ, Hannigan EV, Rothenberg ML (1998) Factors associated with platinum-induced anemia in ovarian cancer patients in Southwest Oncology Group studies. Proc Am Soc Clin Oncol 17: 359a (Abstr 1387)Google Scholar
  95. 95.
    Henke M (2001) Correction of cancer anemia–impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy. Onkologie 24: 450–454PubMedCrossRefGoogle Scholar
  96. 96.
    Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21 (Suppl 3): 21–28PubMedGoogle Scholar
  97. 97.
    Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D (2001) Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol Oncol 81: 485–489PubMedCrossRefGoogle Scholar
  98. 98.
    Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G, Ahmed F, Hickish T, Nicolson M, O’Brien M, Iveson T, Iveson A, Evans.0 (1995) Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317–2323Google Scholar
  99. 99.
    Hirst DG (1986) Anemia: A problem or an opportunity in radiotherapy. Int J Radiat Oncol Biol Phys 12: 2009–2017PubMedCrossRefGoogle Scholar
  100. 100.
    Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266–276PubMedCrossRefGoogle Scholar
  101. 101.
    Horiguchi H, Kayama F, Oguma E, Willmore WG, Hradecky P, Bunn HF (2000) Cadmium and platinum suppression of erythropoietin production in cell culture: clinical implications. Blood 96: 3743–3747PubMedGoogle Scholar
  102. 102.
    Hoskins PJ, Swenerton KD (1994) Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12: 60–63PubMedGoogle Scholar
  103. 103.
    Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58–65PubMedGoogle Scholar
  104. 104.
    Hussain M, Salwen W, Kucuk O, Ensley J (1997) Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Semin Oncol 24 (Suppl 19): S43 - S45Google Scholar
  105. 105.
    Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton R, Burroughs J, Rozencweig M (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257–263PubMedGoogle Scholar
  106. 106.
    Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF (2001) Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res 7: 68–73PubMedGoogle Scholar
  107. 107.
    Jakobsen EB, Eickhoff JH, Andersen JP, Ottesen M (1994) Prognosis after nephrectomy for renal cell carcinoma. Scand J Urol Nephrol 28: 229–236PubMedGoogle Scholar
  108. 108.
    Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, Gozzelino F, Planting A, van Zandwijk N (1993) Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A: 1720–1722Google Scholar
  109. 109.
    Jazieh AR, Hussain M, Howington JA, Spencer HJ, Husain M, Grismer JT, Read RC (2000) Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 70: 1168–1171PubMedCrossRefGoogle Scholar
  110. 110.
    Jones A, Wiltshaw E, Harper P, Slevin M, Shepard J, Mansi J, Blake P, Ian S, Gore M (1992) A randomized study of high vs conventional-dose carboplatin for previously untreated ovarian cancer. Br J Cancer 65 (Suppl 16): 15 (Abstract C8)Google Scholar
  111. 111.
    Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O’Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567–2574PubMedGoogle Scholar
  112. 112.
    Jootar S, Chuncharunee S, Ongphiphaphadhanakul B, Atichartakarn V (1990) Multivariate analysis of prognostic factors in chronic myelogenous leukemia. J Med Assoc Thai 73: 662–669PubMedGoogle Scholar
  113. 113.
    Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2: 837–842PubMedGoogle Scholar
  114. 114.
    Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Cassidy J, Davis JA, Reed NS, Crawford SM, MacLean A, Swapp GA, Sarkar TK, Kennedy JH, Symonds RP (1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329–333PubMedCrossRefGoogle Scholar
  115. 115.
    Keating MJ (1999) Chronic lymphocytic leukemia. Semin Oncol 26 (Suppl 14): 107–114PubMedGoogle Scholar
  116. 116.
    Kosmidis P, Mylonakis N, Fountzilas G, Samantas E, Athanassiadis A, Pavlidis N, Skarlos D (1997) Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 24 (Suppl 12): S30 - S33Google Scholar
  117. 117.
    Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E, Fountzilas G (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 14: 2682–2687Google Scholar
  118. 118.
    Kosty MP, Fleishman SB, Herndon JE, 2nd, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR (1994) Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 12: 1113–1120PubMedGoogle Scholar
  119. 119.
    Kroep JR, Peters GJ, van Moorsel CJA, Catik A, Vermorken JB, Pinedo HM, van Groeningen CJ (1999) Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 10: 1503–1510PubMedCrossRefGoogle Scholar
  120. 120.
    Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ (1996) Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552–1557Google Scholar
  121. 121.
    Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16: 1068–1074Google Scholar
  122. 122.
    Kumar P (2000) Impact of anemia in patients with head and neck cancer. Oncologist 5: 13–18CrossRefGoogle Scholar
  123. 123.
    Kyle RA (1975) Multiple myeloma: review of 869 cases. Mayo Clin Proc 50: 29–40PubMedGoogle Scholar
  124. 124.
    Lammering G, Carl UM, Pape H, Hartmann KA (1999) [Changes in hemoglobin concentrations in combined radio-and chemotherapy in locally advanced ORL tumors]. Strahlenther Onkol 175: 559–562Google Scholar
  125. 125.
    Langer CT, Leighton JC, Comis RL, O’Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860–1870PubMedGoogle Scholar
  126. 126.
    Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H (1998) Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85–27. Int J Radiat Oncol Biol Phys 42: 1069–1075PubMedCrossRefGoogle Scholar
  127. 127.
    Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535–2542PubMedCrossRefGoogle Scholar
  128. 128.
    Leonard RC, Hayward RL, Prescott RJ, Wang JX (1991) The identification of discrete prognostic groups in low grade non-Hodgkin’s lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 2: 655–662Google Scholar
  129. 129.
    Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B for the Epoetin Alfa Study Group (2001a) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a rendomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874Google Scholar
  130. 130.
    Littlewood TJ (2001b) The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28 (Suppl 8): 49–53PubMedCrossRefGoogle Scholar
  131. 131.
    Loehrer PJ Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH (1995) Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 13: 2594–2599PubMedGoogle Scholar
  132. 132.
    Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M (2000) Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164: 53–56PubMedCrossRefGoogle Scholar
  133. 133.
    Luikart SD, Goutsou M, Mitchell ED, Van Echo DA, Modeas CR, Propert KJ, O’Donnell J, Difino S, Perry MC, Green MR (1993) Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol 16: 127–131Google Scholar
  134. 134.
    Matsumoto T, Endoh K, Kamisango K, Akamatsu KI, Koizumi K, Higuchi M, Imai N, Mitsui H, Kawaguchi T (1990) Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol 75: 463–468PubMedCrossRefGoogle Scholar
  135. 135.
    McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589–1599PubMedGoogle Scholar
  136. 136.
    McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589–1599PubMedGoogle Scholar
  137. 137.
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6PubMedCrossRefGoogle Scholar
  138. 138.
    McLaren CE, Holcombe RF, Wong WM (2000) Patient-specific sequential analysis to monitor cisplatin-induced anemia. Proc Am Soc Clin Oncol 19: 640a (Abstract 2527)Google Scholar
  139. 139.
    Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson WE, Frank GL, Leber BF, Sternbach MS, Foster GA, Skingley P, Levine MN (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J Clin Oncol 13: 2386–2393PubMedGoogle Scholar
  140. 140.
    Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR (1995a) Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13: 1871–1879PubMedGoogle Scholar
  141. 141.
    Miller AA, Niell HB, Griffin JP (1995b) Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 12: 59–65PubMedCrossRefGoogle Scholar
  142. 142.
    Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KM, Venkatraman ES, Woolley K, Heelan RT, Kris MG (1995c) Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968–972PubMedCrossRefGoogle Scholar
  143. 143.
    Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, Smith JG, Toner GC, Rischin D, Bell DR (1996) Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14: 142–148PubMedGoogle Scholar
  144. 144.
    Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B (1998) Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 9: 1109–1115PubMedCrossRefGoogle Scholar
  145. 145.
    Mounier N, Morel P, Haioun C, Coiffier B, Tilly H, Chatelain C, Lederlin P, Thyss A, Herbrecht R, Gisselbrecht C, Lepage E (1998) A multivariate analysis of the survival of patients with aggressive lymphoma. Cancer 82: 1952–1962PubMedCrossRefGoogle Scholar
  146. 146.
    Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff ICH, Hong WK (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384–388PubMedCrossRefGoogle Scholar
  147. 147.
    Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858–1867PubMedGoogle Scholar
  148. 148.
    Nagao K, Fukuoka M, Fujita A, Kurita Y, Saito R, Niitani H, Negoro S, Katakami N, Nakano M (2000) [A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group]. Gan To Kagaku Ryoho 27: 413–421Google Scholar
  149. 149.
    Nowrousian MR, Schmidt CG (1982) Effects of cisplatin on different haemopoietic progenitor cells in mice. Br J Cancer 46: 397–402PubMedCrossRefGoogle Scholar
  150. 150.
    Nowrousian MR, Kasper C, Oberhoff C, et al (1996) Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythropoietin in Cancer Supportive Treatment. Marcel Dekker, New York, pp 13–34Google Scholar
  151. 151.
    Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G (1998) The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 83: 726–731PubMedCrossRefGoogle Scholar
  152. 152.
    O’Rourke M, Crawford J, Schiller J, Laufman L, Yanovich S, Ozer H, Langleben A, Barlogie B, Koletsky A, Clamon G, Purvis J, Tuttle R, Hohneker J (1993) Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine® in a randomized controlled trial. Am Soc Clin Oncol 12: 343 (Abstract)Google Scholar
  153. 153.
    Oettle H, Riess H, Raguse JD, Bier J, Gath HF (2001) Recombinant human erythropoietin in the treatment of head and neck tumor anaemia. Int J Oral Maxillofac Surg 30: 148–155PubMedCrossRefGoogle Scholar
  154. 154.
    Oivanen TM (1996) Plateau phase in multiple myeloma: an analysis of longterm follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 92: 834–839PubMedCrossRefGoogle Scholar
  155. 155.
    Okamoto H, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Kunikane H, Karato A, Ohmatsu H, Yamakido M (1992) Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 3: 819–824PubMedGoogle Scholar
  156. 156.
    Overgaard J, Hansen HS, Jorgensen K, et al (1986) Primary radiotherapy of larynx and pharynx carcinoma–An analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 12: 515–521PubMedCrossRefGoogle Scholar
  157. 157.
    Paredes J, Hong WK, Felder TB, Dimery IW, Choksi AJ, Newman RA, Castellanos AM, Robbins KT, McCarthy K, Atkinson N, Kramer AM, Hersh EM, Goepfert H (1988) Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 6: 955–962PubMedGoogle Scholar
  158. 158.
    Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS, Benetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7: 1419–1426Google Scholar
  159. 159.
    Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87: 676–681PubMedCrossRefGoogle Scholar
  160. 160.
    Pines A, Ben-Bassat I, Modan M, Blumstein T, Ramot B (1987) Survival and prognostic factors in chronic lymphocytic leukemia. Eur J Haematol 38: 123–130PubMedCrossRefGoogle Scholar
  161. 161.
    Pirker R, Krajnik G, Zochbauer S, Malayeri R, Kneussl M, Huber H (1995) Paclitaxel/cisplatin in advanced non-small-cell lung cancer ( NSCLC ). Ann Oncol 6: 833–835Google Scholar
  162. 162.
    Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, Schneider M, Magne N, Bensadoun RJ, Renee N, Milano G (2000) An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 36: 852–857PubMedCrossRefGoogle Scholar
  163. 163.
    Postmus PE, Giaccone G, Debruyne C, Sahmoud T, Splinter TA, van Zandwijk N (1996) Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer. Cooperative Group. Semin Oncol 23 (Suppl 12): 10–13PubMedGoogle Scholar
  164. 164.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234PubMedGoogle Scholar
  165. 165.
    Ranson MR, Jayson G, Perkins S, Anderson H, Thatcher N (1997) Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. Semin Oncol 24 (Suppl 12): S6 - S9Google Scholar
  166. 166.
    Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879–2885PubMedGoogle Scholar
  167. 167.
    Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 17: 2840–2846PubMedGoogle Scholar
  168. 168.
    Robert F, Wheeler RH, Molthrop D, Bailey A, Chen S (1994) Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. Am J Clin Oncol 17: 383–386PubMedCrossRefGoogle Scholar
  169. 169.
    Rose PG, Blessing JA, Mayer AR, Homesley HD (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16: 405–410PubMedGoogle Scholar
  170. 170.
    Rossof AH, Slayton RE, Perlia CP (1972) Preliminary clinical experience with cis diamminedichloroplatinum (II) (NSC 119875, CACP ). Cancer 30: 14511456Google Scholar
  171. 171.
    Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128–1135PubMedGoogle Scholar
  172. 172.
    Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251–260PubMedGoogle Scholar
  173. 173.
    Rozencweig M, Martin A, Beltangady M, Bragman K, Goodlow J, Wiltshaw E, Calvert H, Mongioni C, Pecorelli S, Bolis G, Rocker I, Adams M, Canetta R (1990) Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In: Bunn PA, Canetta R, Ozols RF, Rozencweig M (eds) Carboplatin: current perspectives and future directions. Saunders, Philadelphia (PA), pp 175–186Google Scholar
  174. 174.
    Rytting M, Worth L, Jaffe N (1996) Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 10: 365–376PubMedCrossRefGoogle Scholar
  175. 175.
    Sanchiz F, Milla A (1994) Tegafur-uracil ( UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 24: 322–326Google Scholar
  176. 176.
    Saylors RL, 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19: 3463–3469PubMedGoogle Scholar
  177. 177.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14: 2345–2352PubMedGoogle Scholar
  178. 178.
    Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152–1159PubMedGoogle Scholar
  179. 179.
    Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, Capnist G, Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio LP, Perrotta A, Rosso R, Damasio E, Rizzoli V (1994) MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 12: 1366–1374PubMedGoogle Scholar
  180. 180.
    Shasha D (2001) The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 38 (Suppl 7): 8–15PubMedCrossRefGoogle Scholar
  181. 181.
    Shepherd FA, Cormier Y, Burkes R, Evans WK, Goss G, Klimo P, Feld R, Taylor M (1997) Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24 (Suppl 8): S27 - S30Google Scholar
  182. 182.
    Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM (1998) Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 1325–1330PubMedGoogle Scholar
  183. 183.
    Silver DF, Piver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 73: 280–284Google Scholar
  184. 184.
    Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouvas G, Theocharis E, Panousaki E, Boleti E, Sphakianoudis G, Pavlidis N (1994) Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5: 601–607Google Scholar
  185. 185.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G (1997) Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 24 (Suppl 15): S57 - S61Google Scholar
  186. 186.
    Skillings JR, Rogers-Melamed I, Nabholtz JM, Sawka C, Gwadry-Sridhar F, Moquin JP, Rubinger M, Ganguly P, Burnell M, Shustik C, Dryer D, McLaughlin M, White D, Mertens W (1995) An epidemiological review of anaemia in cancer chemotherapy in Canada. Eur J Cancer 31A (Suppl 5): S183 (Abstract 879)CrossRefGoogle Scholar
  187. 187.
    Skillings JR, Rogers-Melamed I, Nabholtz JM, Sawka C, Gwadry-Sridhar F, Moquin JP, Rubinger M, Ganguly P, Burnell M, Shustik C, Dryer D, McLaughlin M, White D (1999) An epidemiological review of red cell transfusions in cancer chemotherapy. Cancer Prey Control 3: 207–212Google Scholar
  188. 188.
    Skillings JR, Sridhar FG, Wong C, et al (1993) The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16: 22–25Google Scholar
  189. 189.
    Smaniotto D, Luzi S, Morganti AG, Cellini N (2000) Prognostic significance of anemia and role of erythropoietin in radiation therapy. Tumori 86: 17–23PubMedGoogle Scholar
  190. 190.
    Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley JF (1996) Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Invest New Drugs 14: 403–407Google Scholar
  191. 191.
    Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye SB (1994) Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A: 1058–1060Google Scholar
  192. 192.
    Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncrossresistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8: 1173–1186PubMedGoogle Scholar
  193. 193.
    Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M (2001) Recombinant human erythropoietin increases the radiosensitivity of xeno-grafted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127: 346–350PubMedCrossRefGoogle Scholar
  194. 194.
    Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M, Ohashi Y (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31–37PubMedCrossRefGoogle Scholar
  195. 195.
    Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7: 1672–1676PubMedGoogle Scholar
  196. 196.
    Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O’Connell G, MacLean G, et al (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10: 718–726PubMedGoogle Scholar
  197. 197.
    Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139–168PubMedCrossRefGoogle Scholar
  198. 198.
    Teicher BA (1995) Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 9: 475–506PubMedGoogle Scholar
  199. 199.
    Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50: 3339–3344PubMedGoogle Scholar
  200. 200.
    ten Bokkel Huinink W, Gore M, Carmichail J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spancynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183–2193Google Scholar
  201. 201.
    Thatcher N (1994) Controlled study of the efficacy and safety of recombinant human erythropoietin (epoetin alfa; Cilag) in the prevention of anaemia in patients with small cell lung cancer receiving chemotherapy. Ann Oncol 5 (Suppl 8): 89Google Scholar
  202. 202.
    Thatcher N (1998) Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 25 (Suppl 7): 23–26PubMedGoogle Scholar
  203. 203.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–994CrossRefGoogle Scholar
  204. 204.
    Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78: 752–756PubMedCrossRefGoogle Scholar
  205. 205.
    Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61: 1358–1361PubMedGoogle Scholar
  206. 206.
    Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12: 1748–1753PubMedGoogle Scholar
  207. 207.
    Tomida A, Tsuruo T (1999) Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 14: 169–177PubMedGoogle Scholar
  208. 208.
    Unami A, Nishina N, Terai T, Sato S, Tamura T, Noda K, Mine Y (1996) Effects of cisplatin on erythropoietin production in rats. J Toxicol Sci 21: 157–165PubMedCrossRefGoogle Scholar
  209. 209.
    Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886–2894PubMedGoogle Scholar
  210. 210.
    Veach S, Waltzman R, McGuckin J, Goodrich K, Spriggs D (1998) A retrospective analysis of transfusion requirements according to salvage regimen in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 17: 376a (Abstract)Google Scholar
  211. 211.
    Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15: 625–631PubMedGoogle Scholar
  212. 212.
    von Pawel J, Wagner H, Niederle N, Heider A, Koschel G, Gromotka E, Hanske M (1996) Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial. Semin Oncol 23 (Suppl 12): 7–9Google Scholar
  213. 213.
    Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Müller MK, Krech R, Koch O (2000) Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol 176: 73–80PubMedCrossRefGoogle Scholar
  214. 214.
    Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722–2730PubMedGoogle Scholar
  215. 215.
    Wigren T, Oksanen H, Kellokumpu-Lehtinen P (1997) A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 123: 259–266PubMedGoogle Scholar
  216. 216.
    Wiltshaw E, Kroner T (1976) Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60: 55–60PubMedGoogle Scholar
  217. 217.
    Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH (1995) Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 13: 1615–1622PubMedGoogle Scholar
  218. 218.
    Wood PA, Hrushesky JM (1995) Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 95: 1650–1659PubMedCrossRefGoogle Scholar
  219. 219.
    Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459–2465PubMedGoogle Scholar
  220. 220.
    Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K (1998) Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 68: 11–18PubMedCrossRefGoogle Scholar
  221. 221.
    Young SD, Hill RP (1990) Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 82: 371–380PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Department of Internal Medicine (Cancer Research), West German Cancer CenterUniversity of Essen Medical SchoolEssenGermany

Personalised recommendations